Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
Coverage (18)
-
-
ATAI Stock Soars On Eli Lilly’s $2.8B Buyout Yahoo Finance · 60d ago broke it first
-
-
-
-
-
-
-
-
-
-
Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple Yahoo Finance · 60d ago broke it first
-
-
-
-
-
-
Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion Yahoo Finance · 60d ago broke it first
What happened
- Velocity & Diffusion: Coverage escalated across 12 distinct news outlets with 18 published articles, achieving a live velocity of 16.
- Primary Driver: Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
- Predictive Outlook: Newsylist algorithmic models forecast this story will fade from trending status over the next 24 hours.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
Eli Lilly is in discussions to acquire AtaiBeckley, a company focused on the development of psychedelic drugs. Following reports of these negotiations, AtaiBeckley shares experienced substantial growth in after-hours trading.
Coverage from Bloomberg News, Reuters, TradingView, Seeking Alpha, and Yahoo Finance highlights the market reaction, noting significant increases in stock value. Analysts and financial reports have identified the company as a notable stock under $10.
Future developments depend on whether the reported buyout discussions result in a finalized agreement. Coverage does not yet specify the terms of any potential deal or the timeline for a formal announcement.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 60d ago.
Questions people are asking
What is driving the movement in AtaiBeckley stock?
The increase in share price is linked to reports regarding potential buyout discussions with Eli Lilly.
Has a deal between Eli Lilly and AtaiBeckley been finalized?
No. Coverage indicates that Eli Lilly is currently nearing a deal, but reports do not confirm a final agreement.
How much has AtaiBeckley's stock risen?
Market reports indicate stock increases ranging between 59% and 66% during after-hours trading.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
Stock futures fall as investors weigh AI safety concerns, oil gains: Live updates
Stock futures slide as major tech lab CEOs unite to urge a slowdown in artificial intelligence development.
Stock Market Today: Dow tumbles 1%, S&P 500 and Nasdaq drop as Brent crude edges toward $100 a barrel and pharma stocks stumble
Wall Street extends losses as major indexes slide, pharmaceutical shares drop, and oil surges amid geopolitical tensions.
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance to a new Alzheimer’s disease blood test developed by Roche and Eli Lilly.
Hugging Face has been fielding M&A interest for a deal worth at least $13 billion
AI platform Hugging Face is exploring a sale valuing the company at $13 billion.
Stock Market Today: Dow Opens Higher, Bond Yields Dive After Treasury Steps Up Buybacks
The Treasury Department doubled its debt buybacks, driving US bond yields lower and prompting a market rally.
Target is set to report earnings before the bell. Here's what to expect
Target prepares to report its second-quarter earnings before the opening bell.